<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723084</url>
  </required_header>
  <id_info>
    <org_study_id>M15-828</org_study_id>
    <nct_id>NCT02723084</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection</brief_title>
  <acronym>CERTAIN-2</acronym>
  <official_title>A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 8 weeks of treatment with
      the combination regimen ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12
      weeks in Hepatitis C Virus Genotype 2 (GT2) infected participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 8, 2016</start_date>
  <completion_date type="Actual">March 24, 2017</completion_date>
  <primary_completion_date type="Actual">January 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieve 12-week sustained virologic response (SVR12) (non-inferiority analysis)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification. The primary outcome measure is the non-inferiority analysis of the SVR12 rate of the ABT-493/ABT-530 arm to that of the SOF/RBV arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants treated with ABT-493/ABT-530 who achieve 12-week sustained virologic response (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure</measure>
    <time_frame>Up to 12 weeks while on treatment</time_frame>
    <description>The percentage of subjects with confirmed greater than 1 log10 IU/mL increase in HCV RNA above nadir during treatment, or with confirmed HCV RNA greater than or equal to 100 IU/mL after achieving unquantifiable HCV RNA during treatment, or with quantifiable HCV RNA at the end of treatment with at least 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Post-Treatment relapse</measure>
    <time_frame>Up to 12 weeks after the last dose of study drug</time_frame>
    <description>Percentage of participants with confirmed quantifiable HCV RNA after completion of treatment among participants with unquantifiable HCV RNA at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Chronic Hepatitis C Virus</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530, GT2 without cirrhosis (8 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 in HCV GT2 infected participants without cirrhosis for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sofosbuvir plus ribavirin in HCV GT2 infected participants without cirrhosis for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530, GT2 without cirrhosis (8 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Capsule</description>
    <arm_group_label>sofosbuvir plus ribavirin, GT2 without cirrhosis (12 wks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening central laboratory result indicating HCV GT-2 infection without co-infection
             of any other genotype.

          -  Subject has positive anti-HCV Ab and plasma HCV RNA viral load greater than or equal
             to 1000 IU/mL at Screening Visit.

          -  Chronic HCV infection defined as one of the following:

               -  Positive for anti-HCV antibody (Ab) and/or HCV RNA at least 6 months before
                  Screening; or

               -  A liver biopsy consistent with chronic HCV infection.

          -  Subject must be HCV Direct-acting antiviral agent (DAA) treatment-na√Øve (i.e., patient
             has not received a single dose of any approved or investigational DAA). Prior HCV
             treatment using IFNs with or without ribavirin is acceptable. Previous HCV Interferon
             (IFN) based treatment must have been completed greater than or equal to 2 months prior
             to screening.

        Exclusion Criteria:

          -  Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti
             human immunodeficiency virus antibody (HIV Ab).

          -  Requirement for and inability to safely discontinue contraindicated medications or
             supplements at least 2 weeks or 10 half-lives (whichever is longer) prior to the first
             dose of any study drug.

          -  Clinically significant abnormalities, other than HCV-infection, based upon the results
             of a medical history, physical examination, vital signs, laboratory profile, and a
             12-lead electrocardiogram (ECG) that make the subject an unsuitable candidate for this
             study in the opinion of the investigator, including, but not limited to:

               -  Uncontrolled diabetes as defined by a glycated hemoglobin (hemoglobin A1C) level
                  &gt; 8.5% at the Screening Visit.

               -  Active or suspected malignancy or history of malignancy (other than basal cell
                  skin cancer or cervical carcinoma in situ) in the past 5 years, or any history of
                  HCC.

               -  Uncontrolled cardiac, respiratory, gastrointestinal, hematologic, neurologic,
                  psychiatric, or other medical disease or disorder, which is unrelated to the
                  existing HCV infection.

          -  Any cause of liver disease other than chronic HCV-infection, including but not limited
             to the following:

               -  Hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's disease, autoimmune
                  hepatitis, alcoholic liver disease, or steatohepatitis considered to be the
                  primary cause of the liver disease rather than concomitant/incidental with HCV
                  infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koji Kato, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shinbeppu Hospital /ID# 148636</name>
      <address>
        <city>Beppu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital /ID# 148511</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuiken Saiseikai Hospital /ID# 148631</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center /ID# 148536</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital /ID# 148549</name>
      <address>
        <city>Fukuoka-shi,Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital /ID# 148537</name>
      <address>
        <city>Gifu-shi, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital /ID# 148510</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center /ID# 148528</name>
      <address>
        <city>Gifu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital /ID# 148509</name>
      <address>
        <city>Hamamatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital /ID# 148302</name>
      <address>
        <city>Hiroshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Society Himeji Hospital /ID# 148524</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeda Municipal Hospital /ID# 148514</name>
      <address>
        <city>Ikeda-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Chiba Hokusoh Hospital /ID# 148538</name>
      <address>
        <city>Inzai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital /ID# 148553</name>
      <address>
        <city>Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital /ID# 148299</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Municipal Tama Hospital /ID# 148541</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital /ID# 148515</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital /ID# 148517</name>
      <address>
        <city>Kanazawa-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital /ID# 148527</name>
      <address>
        <city>Kashihara-shi, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital Kajigaya /ID# 148303</name>
      <address>
        <city>Kawasaki-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Shinto General Hospital /ID# 148551</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital /ID# 148526</name>
      <address>
        <city>Kyoto-shi, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital,Kyoto Prefectural University of Medicine /ID# 148508</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital /ID# 148633</name>
      <address>
        <city>Maebashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital /ID# 148521</name>
      <address>
        <city>Matsumoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ehime Prefectural Central Hospital /ID# 148534</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital /ID# 148535</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mishuku Hospital /ID# 148544</name>
      <address>
        <city>Meguro-ku , Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital /ID# 148531</name>
      <address>
        <city>Nagasaki-shi, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital /ID# 148539</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital /ID# 148548</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital /ID# 148632</name>
      <address>
        <city>Nishinomiya-shi, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital /ID# 148516</name>
      <address>
        <city>Obihiro-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital /ID# 148523</name>
      <address>
        <city>Ogaki-shi,Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital /ID# 148300</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School /ID# 148543</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital /ID# 148550</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Red Cross Hospital /ID# 148504</name>
      <address>
        <city>Osaka-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital /ID# 148638</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital /ID# 148540</name>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital /ID# 148505</name>
      <address>
        <city>Saga-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Saitama Hospital /ID# 148513</name>
      <address>
        <city>Saitama-shi, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center /ID# 148547</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital /ID# 148301</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital /ID# 148545</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital /ID# 148630</name>
      <address>
        <city>Shimotsuga-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Suita Hospital /ID# 148520</name>
      <address>
        <city>Suita-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital /ID# 148518</name>
      <address>
        <city>Suita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital /ID# 148503</name>
      <address>
        <city>Takamatsu-shi, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital OrganizationTakasaki GeneralMedical Center /ID# 148925</name>
      <address>
        <city>Takasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University, Kitasato Institute Hospital /ID# 148552</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo University Hospital /ID# 148530</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital /ID# 148634</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital /ID# 148533</name>
      <address>
        <city>Toyoake-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 148506</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital /ID# 148542</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center /ID# 148529</name>
      <address>
        <city>Yokohama-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minami Kyousai Hospital /ID# 148525</name>
      <address>
        <city>Yokohama-shi, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital /ID# 148546</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oita University Hospital /ID# 148637</name>
      <address>
        <city>Yufu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Non-cirrhotic</keyword>
  <keyword>Hepatitis C Genotype 2</keyword>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

